FDA Approves Moderna's mRNA Flu Vaccine for Older Adults

Why it matters locally: The approval of Moderna's mRNA flu vaccine for adults 50 and older has particular relevance for West Virginia, which has one of the nation's oldest populations. This new vaccine option could impact public health strategies and vaccine accessibility for a significant portion of the state's residents, especially those in rural areas served by local health departments and medical centers.

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, mFlusiva. This approval specifically covers adults aged 50 and older. mFlusiva represents a new type of flu shot entering the market. Moderna developed the vaccine using messenger RNA (mRNA) technology. This technology differs from traditional vaccine methods, which often use inactivated or weakened forms of the virus. Regulators granted approval for mFlusiva following a review of clinical data. The vaccine aims to protect against seasonal influenza. The target demographic for this shot includes individuals at higher risk of complications from the flu.